Enovis (NYSE:ENOV) Stock Gets Price Target Boost from Needham & Company LLC

Enovis (NYSE:ENOV) had its target price upped by research analysts at Needham & Company LLC from $34.00 to $38.00 in a research note issued on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Needham & Company LLC‘s price objective suggests a potential upside of 39.92% from the company’s previous close.

A number of other analysts also recently issued reports on ENOV. Wells Fargo & Company lowered their price target on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a report on Wednesday, September 2nd. Zacks Research raised shares of Enovis from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 29th. Wall Street Zen raised shares of Enovis from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Citizens Jmp decreased their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research report on Wednesday, September 2nd. Finally, Canaccord Genuity Group lowered their target price on shares of Enovis from $50.00 to $45.00 and set a “buy” rating on the stock in a research note on Monday, August 17th. Ten analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.62.

Enovis Stock Performance

ENOV stock traded down $1.46 during trading on Thursday, hitting $27.16. 2,304,734 shares of the company traded hands, compared to its average volume of 1,449,886. The stock’s 50-day simple moving average is $19.91 and its 200 day simple moving average is $23.09. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.98 and a quick ratio of 1.00. The company has a market cap of $1.57 billion, a PE ratio of -2.95 and a beta of 1.31. Enovis has a 1 year low of $16.70 and a 1 year high of $32.41.

Enovis (NYSE:ENOV) last released its quarterly earnings data on Thursday, November 5th. The company reported $0.88 EPS for the quarter, topping the consensus estimate of $0.77 by $0.11. The business had revenue of $558.73 million for the quarter, compared to analyst estimates of $557.12 million. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%. The business’s quarterly revenue was up 1.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.75 EPS. On average, equities analysts expect that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Oliver Engert acquired 5,140 shares of the firm’s stock in a transaction on Thursday, September 3rd. The shares were acquired at an average cost of $19.46 per share, with a total value of $100,024.40. Following the completion of the acquisition, the insider directly owned 61,238 shares in the company, valued at approximately $1,191,691.48. This trade represents a 9.16% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Damien Mcdonald acquired 13,035 shares of the firm’s stock in a transaction on Friday, September 4th. The shares were bought at an average cost of $19.15 per share, for a total transaction of $249,620.25. Following the completion of the acquisition, the chief executive officer owned 247,077 shares of the company’s stock, valued at approximately $4,731,524.55. This represents a 5.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders have bought a total of 23,293 shares of company stock worth $449,599 in the last quarter. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

A number of institutional investors and hedge funds have recently modified their holdings of ENOV. Allworth Financial LP increased its position in shares of Enovis by 59.7% during the second quarter. Allworth Financial LP now owns 1,744 shares of the company’s stock worth $36,000 after purchasing an additional 652 shares in the last quarter. IFP Advisors Inc raised its stake in Enovis by 5,590.5% in the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after purchasing an additional 1,174 shares during the last quarter. Inspire Investing LLC lifted its holdings in Enovis by 4.9% in the 3rd quarter. Inspire Investing LLC now owns 34,833 shares of the company’s stock valued at $636,000 after purchasing an additional 1,631 shares in the last quarter. Amundi lifted its holdings in Enovis by 2.3% in the 1st quarter. Amundi now owns 74,184 shares of the company’s stock valued at $1,688,000 after purchasing an additional 1,677 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its holdings in Enovis by 9.3% in the 2nd quarter. Handelsbanken Fonder AB now owns 21,117 shares of the company’s stock valued at $437,000 after purchasing an additional 1,800 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis News Roundup

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Q3 adjusted earnings were $0.88 per share, beating estimates of about $0.77 and topping $0.75 a year earlier. Revenue of $558.7 million slightly exceeded forecasts and grew 1.8% year over year. Enovis Q3 2026 results
• Positive Sentiment: Enovis raised its 2026 EPS guidance to $3.58–$3.79, signaling improved earnings expectations. Guidance and repurchase announcement
• Positive Sentiment: The company authorized a $200 million share-repurchase program, which could support per-share results and signal confidence in its prospects. Share-buyback announcement
• Positive Sentiment: Wells Fargo raised its target to $37 and maintained an Overweight rating; Needham lifted its target to $38 and BTIG to $42, both with Buy ratings. Wells Fargo analyst rating
• Neutral Sentiment: Canaccord lowered its price target from $45 to $42 but kept a Buy rating. Reports also highlighted product innovation and market-share gains, though market volatility remains a factor. Product innovation and share gains

About Enovis

Enovis Corporation (NYSE: ENOV) is a medical technology company that develops, manufactures and distributes products designed to improve patient recovery, mobility and quality of life. Its portfolio serves orthopedic, sports medicine, physical therapy and rehabilitation markets, as well as other areas of musculoskeletal care.

The company’s products include orthopedic implants and surgical technologies, braces and supports, cold and compression therapy systems, electrotherapy and rehabilitation equipment, and other solutions used by hospitals, surgeons, physical therapists, athletic trainers and patients.